Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
|Articles|September 30, 2014
Segment 11 - Why It Is an Exciting Time for Immuno-Oncology
The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.
Advertisement
The panelists offer their closing remarks regarding immuno-oncology’s promises and challenges.
Jianda Yuan, MD, PhD, explains why this is an exciting time for immunotherapy, and Kimberly Shafer-Weaver, PhD, added that discussing immuno-oncology early on is important so that the best decisions can be made for not only patients, but also the payers.
“Sometimes, it is tempting, I think, to get discouraged that the innovations that we are seeing are going to come at a price tag that we cannot afford,” Michael Kolodziej, MD, added in conclusion. “I think that is a mistake. I think that what we should be focused on is really finding out how much these innovations truly add to what we are doing now and who benefits the most.”
Advertisement
Related to this article
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Advertisement
Advertisement
Trending on AJMC
1
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
4
Closing Screening Gaps for Cardio-Kidney-Metabolic Disease
5